Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study

Mengqing Xie(Tongji University), Chunxia Su(Tongji University), Yan Wu(University of Washington), Tao Hu(Howard Hughes Medical Institute), Yujia Fang(Zhejiang Center for Disease Control and Prevention), Xianxiu Ji(Tongji University), Changbin Zhu(Dian Diagnostics (China)), Qi Wang(Tongji University), Lin Wu(Materials Systems (United States)), Xin Yu(Harvard University), Jin Wang(Stony Brook University), Li Liu(Air Force Medical University), Jing Zhao(University of Electronic Science and Technology of China), Xiangling Chu(Tongji University), Shiji Zhang(Tongji University), Xiaorong Dong(The University of Melbourne), Minwei Bao(Tongji University)
Signal Transduction and Targeted Therapy
May 22, 2025
10.1038/s41392-025-02252-5
Cited by 6

Related Papers

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
|Proceedings of the National Academy of Sciences|2007|598
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508